KBC Group’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42K Hold
1,484
﹤0.01% 1714
2025
Q4
$59K Hold
1,484
﹤0.01% 1578
2025
Q3
$52K Hold
1,484
﹤0.01% 1635
2025
Q2
$49K Sell
1,484
-876
-37% -$28.5K ﹤0.01% 1612
2025
Q1
$76K Hold
2,360
﹤0.01% 1623
2024
Q4
$72K Buy
2,360
+932
+65% +$30K ﹤0.01% 1718
2024
Q3
$40K Hold
1,428
﹤0.01% 1781
2024
Q2
$33K Buy
1,428
+270
+23% +$6.23K ﹤0.01% 1796
2024
Q1
$35K Hold
1,158
﹤0.01% 1710
2023
Q4
$41K Hold
1,158
﹤0.01% 1658
2023
Q3
$51K Buy
+1,158
New +$56.5K ﹤0.01% 1427

Other funds holding ATRC

KBC Group's ATRC Position: Q1 2026 in Review

KBC Group held its AtriCure (ATRC) position steady in Q1 2026 at 1,484 shares worth $42K. The position accounts for ﹤0.01% of the portfolio, ranked #1714.

KBC Group first reported a position in ATRC in Q3 2023 and has held it in 11 quarters since. The position peaked at $76K in Q1 2025. 223 funds tracked by Wall St. Rank hold ATRC as of Q1 2026.

  • KBC Group held 1,484 shares of AtriCure worth $42K as of Q1 2026.
  • KBC Group left its AtriCure share count unchanged in Q1 2026.
  • AtriCure made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1714 holding.
  • KBC Group first reported a position in AtriCure in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's AtriCure position peaked at $76K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held AtriCure as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.